The US Food and Drug administration has accepted a new drug application for GlaxoSmithKline’s treatment for myelofibrosis patients with anaemia, the company said on Wednesday.
The application for the drug, known as Momelotinib, is based on the results from key phase III trials, which met all primary and key secondary endpoints, GSK added.
Momelotinib is not currently approved in any market.
Reporting by Frank Prenesti at Sharecast.com
